Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

For weight loss drug leaders, the last two weeks have been nothing short of disastrous for shares. Industry pioneer Novo Nordisk A/S (NYSE: NVO) saw its stock drop nearly 22% on July 29 after lowering ...